Helus Pharma Inc.

US$8.96As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:HELPHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (21.41%)
Div yield —
ROE (86.94%)
Biotechnology
Beta (5Y) 0.62
PE TTM —
TSR TTM 23.42%
Mkt cap US$654.6M
ROIC (47.63%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$12
28.71%
75.48%
Hold 11|3|1|1|10
3Q26
4Q26
1Q27
2Q27
Earnings per share$
0.16
0.16
0.18
0.19
26.08%
37.21%
39.17%
34.37%
Revenue$M
29.95
30.70
32.50
34.07
(2.62%)
1.17%
8.45%
10.66%
Peers (US$654.6M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.684
0.037
0.034
EBIT/Intx
9.916
1.017
0.797
Own earn%
(127.36)
75.56
39.21
Sh yield%
31.74
56.74
56.32
Owners
Insiders/Inst%
3.35
80.33
Short interest%
4.41
SBC / revenue%
3.40
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
36–42
$1 testx
—
Incr. ROIC%
20